Breaking News
Get Actionable Insights with InvestingPro+: Start 7 Day FREE Trial Register here
Investing Pro 0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details
Close

Evotec AG O.N. (EVTG)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
26.960 -0.120    -0.44%
11:35:19 - Closed. Currency in EUR ( Disclaimer )
Type:  Equity
Market:  Germany
ISIN:  DE0005664809 
WKN:  566480
  • Volume: 223,706
  • Bid/Ask: 0.000 / 0.000
  • Day's Range: 26.760 - 27.610
Evotec AG 26.960 -0.120 -0.44%
IndustryLife Sciences Tools & Services
SectorHealthcare
Employees

4198

Equity Type

ORD

Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.

Contact Information

Phone 49 40 560 81 0
Fax 49 40 560 81 222

Top Executives

Name Age Since Title
Roland Sackers 53 2019 Vice Chairperson of the Supervisory Board
Mario Polywka 58 2004 Independent Member of the Supervisory Board
Elaine Sullivan 60 2015 Independent Member of Supervisory Board
Iris Low-Friedrich 62 2014 Independent Chairperson of the Supervisory Board
Constanze Ulmer-Eilfort 59 2021 Independent Member of Supervisory Board
Camilla Macapili Languille - 2022 Member of the Supervisory Board
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

EVTG Comments

Write your thoughts about Evotec AG O.N.
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Bill Boulton
Bill Boulton Feb 19, 2021 10:01AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
To be fair the stock has had large (lazy) short positions for many months and the US DoD deal is not new news. Also, the sceince of  monoclonal antibodies is still not proven. That said, as a pipeline of royalties begin to come through adding to top lines my outlook remains  €50 target in 3 years.
Daimon van Buren
Daimon van Buren Jan 27, 2021 4:00AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
lol railing Melvin Capital left and right
In Sight
Insight Jan 27, 2021 4:00AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Doesnt have anything to do with that here but rather the us military filing in a huge order at evotec for anti bodies against covid (over the next 7 years)
Bill Boulton
Bill Boulton Mar 04, 2019 10:11AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
155171057981821.jpg
The valuation is very much a "sum of the parts" not a not a future valuation. The potentials from a series of bolt on company purchases and ongoing strategic alliances will see a valuation of €10Bn within the next 5 years. What is not priced in to the current valuation is the vision of the management  and shear quality of the science.. . Volatility is an issue so hold on to your hat !!. . Still not convinced ? Where else could you have got 50%+ return on stocks for the past three years ??
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email